News

Investors might want to bet on Kezar Life Sciences, Inc. (KZR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates

Credicorp (BAP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one

Cardlytics (CDLX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

Ralph Lauren (RL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one

Consensus Cloud Solutions, Inc. (CCSI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

S&P Global (SPGI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Stitch Fix (SFIX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

Cullen/Frost Bankers (CFR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell

Investors might want to bet on Vivos Therapeutics, Inc. (VVOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even

As we enter a new year, the opportunity set in the stock market remains compelling. The US economy has proven more resilient than many expected, the artificial intelligence boom continues to gain

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent

Applied Digital APLD is rebuilding around high-performance compute hosting anchored by multi-year leases and a repeatable financing stack. APLD operates two segments: the legacy Data Center Hosting

At this early hour in pre-market trading, we’re mixed on major market indexes. The Dow is -46 points currently, the S&P 500 is +14, the Nasdaq +144 and the small-cap Russell 2000 +1 point. Over the

Cognizant Technology Solutions CTSH has completed the previously announced acquisition of 3Cloud, a leading Microsoft MSFT Azure services provider. The deal strengthens CTSH’s Azure, data and AI

Shares of Intellia Therapeutics NTLA have plunged 55.2% over the past three months.The steep decline follows a significant regulatory setback related to nexiguran ziclumeran (nex-z), NTLA’s lead

Palantir Technologies PLTR has emerged as one of the strongest-performing enterprise software and artificial intelligence stocks over the past year, delivering an increase of more than 120% and

Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, Mounjaro and Zepbound, Lilly has become the first and only drugmaker to hit a

Qualcomm Incorporated QCOM shares have gained a modest 8.2% over the past year compared with the industry’s growth of 35.7%. Although it has outperformed peers like Hewlett Packard Enterprise